Project Grant R21CA313682
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $446K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park (Roswell Park Comprehensive Cancer Center) received a $639,379 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. The award supports the development and characterization of neuroendocrine bladder carcinoma (NEBC) models to advance understanding of disease pathogenesis and treatment resistance. The project addresses PAR-24-306...
- Federal Project Grant Award Summary Health Research, Inc. Roswell Park Division received a $719,951 Cancer Biology Research grant (CFDA 93.396) from the National Cancer Institute, awarded June 2, 2026, with completion scheduled for May 31, 2031. The project investigates mechanisms underlying lung cancer lineage plasticity that facilitate adaptation and resistance to targeted therapy, specifically addressing how epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LUAD) cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The University of Rochester received a $388,901 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on June 5, 2026, with an ultimate completion date of May 31, 2028. This award funds research investigating the role of the transcriptional co-activator PGC-1A in promoting anti-tumor immunity in colorectal cancer (CRC). The research focuses on PGC-1A gene addition therapy as a potential therapeutic...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This fundamental research initiative addresses immune resistance mechanisms in colorectal cancer (CRC) by investigating the myeloid-stromal axis in the tumor microenvironment. The research will deliver scientific findings on how cancer-associated...
- Federal Grant Award Summary The University of Rochester received a $639,098 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and concluding July 31, 2030. This award supports research targeting intrinsic and extrinsic barriers to metastatic pancreatic ductal adenocarcinoma (PDAC) treatment. The project develops and evaluates an innovative combination therapy approach designed to overcome treatment resistance...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park (operating as Health Research At Roswell Park) received a $713,312 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 1, 2026, with a completion date of May 31, 2031. The grant funds research investigating the impacts of body composition and physical activity on anti-tumor immunity and cancer control in high-grade serous ovarian carcinoma (HGSOC). The...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...